×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
中国医学科学院 北... [41]
中国农业科学院 [2]
复旦大学上海医学院 [2]
上海药物研究所 [1]
山东大学 [1]
中南大学 [1]
更多...
内容类型
期刊论文 [47]
会议论文 [1]
发表日期
2019 [14]
2018 [8]
2017 [8]
2016 [4]
2015 [9]
2014 [2]
更多...
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共48条,第1-10条
帮助
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
作者升序
作者降序
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial
期刊论文
CLINICAL CANCER RESEARCH, 2019, 卷号: 25, 期号: 17, 页码: 5212-5220
作者:
Li, Qiao
;
Guan, Xiuwen
;
Chen, Shanshan
;
Yi, Zongbi
;
Lan, Bo
收藏
  |  
浏览/下载:15/0
  |  
提交时间:2020/07/01
Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world study
期刊论文
2019, 卷号: 8, 期号: 13, 页码: 5823-5830
作者:
Yang Guangjian
;
Ma Di
;
Xu Haiyan
;
Yang Lu
;
Li Junling
收藏
  |  
浏览/下载:3/0
  |  
提交时间:2020/01/03
anaplastic lymphoma kinase inhibitor
crizotinib
crizotinib continuation beyond progressive disease
non-small cell lung cancer
treatment duration
Co-mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer
期刊论文
2019
作者:
Xing Puyuan
;
Han Xiaohong
;
Wang Sha
;
Liu Yutao
;
Yang Sheng
收藏
  |  
浏览/下载:21/0
  |  
提交时间:2020/01/03
circulating tumour DNA
non-small-cell lung cancer
osimertinib
resistance
Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study
期刊论文
2019, 卷号: 31, 期号: 3, 页码: 481-+
作者:
Xing, Puyuan
;
Ma, Di
;
Wang, Qiang
;
Hao, Xuezhi
;
Wang, Mengzhao
收藏
  |  
浏览/下载:15/0
  |  
提交时间:2020/01/03
Crizotinib
anaplastic lymphoma kinase
non-small-cell lung cancer
real-world study
Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I-III Lung Adenocarcinoma
期刊论文
2019, 卷号: 9, 页码: 556
作者:
Han, Xiaohong
;
Tan, Qiaoyun
;
Yang, Sheng
;
Li, Junling
;
Xu, Jianping
收藏
  |  
浏览/下载:19/0
  |  
提交时间:2020/01/03
lung adenocarcinoma
copy number alteration
prognosis
predict
adjuvant chemotherapy
Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial
期刊论文
2019, 卷号: 25, 期号: 17, 页码: 5212-5220
作者:
Li Qiao
;
Guan Xiuwen
;
Chen Shanshan
;
Yi Zongbi
;
Lan Bo
收藏
  |  
浏览/下载:6/0
  |  
提交时间:2020/01/03
Evaluating stress, satisfaction and the associated influencing factors of participants in cancer clinical trials: a cross-sectional study in China
期刊论文
2019, 卷号: 9, 期号: 5, 页码: e028589
作者:
Jiang, Shiyu
;
Liu, Peng
;
Yang, Sheng
;
Yang, Jianliang
;
Wu, Dawei
收藏
  |  
浏览/下载:10/0
  |  
提交时间:2020/01/03
cancer
clinical trials
patient satisfaction
stress
Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment
期刊论文
2019, 卷号: 31, 期号: 2, 页码: 349-356
作者:
Xu, Haiyan
;
Ma, Di
;
Yang, Guangjian
;
Li, Junling
;
Hao, Xuezhi
收藏
  |  
浏览/下载:10/0
  |  
提交时间:2020/01/03
ALK
crizotinib
non-small-cell lung cancer
resistance
sequential therapy
Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib
期刊论文
2019, 卷号: 14, 期号: 3, 页码: 335-342
作者:
Mu, Yuxin
;
Hao, Xuezhi
;
Yang, Ke
;
Ma, Di
;
Wang, Shouzheng
收藏
  |  
浏览/下载:5/0
  |  
提交时间:2020/01/03
Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib
期刊论文
2019, 卷号: 10, 期号: 5, 页码: 1213-1219
作者:
Ma, Di
;
Zhang, Yan
;
Xing, Puyuan
;
Hao, Xuezhi
;
Wang, Mengzhao
收藏
  |  
浏览/下载:5/0
  |  
提交时间:2020/01/03
Anaplastic lymphoma kinase
crizotinib
non-small cell lung cancer
primary resistance
©版权所有 ©2017 CSpace - Powered by
CSpace